Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MPL | P40238 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777625 | 1.00 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1778077 | 0.83 | POLB (0.52) | NPC1RAB9AALDH1A1MAPTHTR3A | |
| SCHEMBL1778079 | 0.83 | POLB (0.52) | NPC1RAB9AALDH1A1MAPTHTR3A | |
| SCHEMBL1777306 | 0.79 | KDM4E (0.47) | SMN1; SMN2ALDH1A1MAPTPOLBHTR2A | |
| SCHEMBL1777304 | 0.79 | KDM4E (0.47) | SMN1; SMN2ALDH1A1MAPTPOLBHTR2A | |
| SCHEMBL9046674 | 0.79 | LTA4H (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20828122 | 0.70 | POLB (0.60) | POLBHTR2AHRH3 | |
| SCHEMBL1255817 | 0.69 | POLB (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23477694 | 0.69 | POLB (0.58) | POLBHTR2AHRH3 | |
| SCHEMBL30475153 | 0.69 | POLB (0.58) | POLBHTR2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | NPC1 1015/4885RAB9A 1592/4885SMN1; SMN2 3381/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | NPC1 706/4885RAB9A 1985/4885SMN1; SMN2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.